Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 8Recurrence 2Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Smoldering Multiple Myeloma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Macular dystrophy, corneal type 1 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Castleman Disease 1Carcinoma, Renal Cell 1Burkitt Lymphoma 1

Interventions

Dexamethasone 17Bortezomib 11pomalidomide 10carfilzomib 6Lenalidomide 4imetelstat 3fludarabine 3daratumumab 3Standard of Care 3Panobinostat 3venetoclax 2siltuximab 2elotuzumab 2Cyclophosphamide 2Arsenic Trioxide 2spartalizumab 1shark cartilage extract 1selinexor 1saracatinib 1ricolinostat 1resiquimod 1poly ICLC 1plitidepsin 1pembrolizumab 1pazopanib 1motexafin gadolinium 1marizomib 1liposomal doxorubicin 1lestaurtinib 1isatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Plasma Cell × siltuximab × Clear all
NCT01219010 2015-01-19

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

Janssen Research & Development, LLC

Phase 1 Completed
30 enrolled
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00402181 2014-05-14

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

Centocor, Inc.

Phase 2 Completed
53 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡